We are live on ! Find out more
CATX icon

Perspective Therapeutics

31 hedge funds and large institutions have $2.63M invested in Perspective Therapeutics in 2019 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

123% more capital invested

Capital invested by funds: $1.18M → $2.63M (+$1.45M)

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

3% more funds holding

Funds holding: 3031 (+1)

0.08% more ownership

Funds ownership: 0.55%0.62% (+0.08%)

Holders
31
Holders Change
+1
Holders Change %
+3.33%
% of All Funds
0.61%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
7
Reduced
4
Closed
5
Calls
Puts
Net Calls
Net Calls Change

CATX Hedge Fund Activity: Q4 2019 in Review

31 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q4 2019, worth a combined $2.63M — up 123% from $1.18M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new CATX positions and 5 closed out — a net gain of 1 holder — while 7 added to existing stakes and 4 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $108K. The largest seller was Virtu Financial, cutting an estimated $22.9K.

  • 31 institutional investors held Perspective Therapeutics (CATX) as of Q4 2019, up from 30 in Q3 2019.
  • Funds reported $2.63M of Perspective Therapeutics stock for Q4 2019, up 123% quarter-over-quarter.
  • 6 funds opened new Perspective Therapeutics positions in Q4 2019 and 5 closed out, a net change of +1 holder.
  • The largest Perspective Therapeutics buyer in Q4 2019 was Renaissance Technologies, an estimated $108K added.
  • The largest Perspective Therapeutics seller in Q4 2019 was Virtu Financial, an estimated $22.9K sold.

Based on aggregated 13F filings for Q4 2019.